These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34988170)

  • 1. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
    Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden.
    Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
    Lenis AT; Ravichandran V; Brown S; Alam SM; Katims A; Truong H; Reisz PA; Vasselman S; Nweji B; Autio KA; Morris MJ; Slovin SF; Rathkopf D; Danila D; Scher HI; Woo S; Vargas HA; Laudone VP; Ehdaie B; Reuter V; Arcila M; Berger MF; Viale A; Schultz N; Gopalan A; Donoghue MTA; Ostrovnaya I; Stopsack KH; Solit DB; Abida W
    Clin Cancer Res; 2024 Jul; ():. PubMed ID: 38949888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
    Choi SJ; Lee JB; Kim JH; Hong MH; Cho BC; Lim SM
    Ther Adv Med Oncol; 2024; 16():17588359241240657. PubMed ID: 38523846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
    Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.
    Ma Y; Li Q; Du Y; Chen W; Zhao G; Liu X; Ye L; Li H; Wang X; Liu J; Shen Z; Ma L; Zhou Y
    Onco Targets Ther; 2020; 13():5191-5198. PubMed ID: 32606739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.
    Zhou H; Sun D; Song S; Niu Y; Zhang Y; Lan H; Cui J; Liu H; Liu N; Hou H
    Discov Oncol; 2024 Jun; 15(1):213. PubMed ID: 38847966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
    Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
    J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.
    Mosalem O; Coston TW; Imperial R; Mauer E; Thompson C; Yilma B; Bekaii-Saab TS; Stoppler MC; Starr JS
    Oncologist; 2024 May; ():. PubMed ID: 38776551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of the human epidermal growth factor receptor 2 (
    Huang H; Wang Z; Li Y; Zhao Q; Niu Z
    J Gastrointest Oncol; 2021 Apr; 12(2):377-387. PubMed ID: 34012633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characteristics of early-onset compared with late-onset colorectal cancer: A case controlled study.
    Tang J; Peng W; Tian C; Zhang Y; Ji D; Wang L; Jin K; Wang F; Shao Y; Wang X; Sun Y
    Int J Surg; 2024 May; ():. PubMed ID: 38742845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients.
    Qiu Q; Tan D; Chen Q; Zhou R; Zhao X; Wen W; Yang P; Li J; Gong Z; Zhang D; Wang M
    Am J Cancer Res; 2024; 14(2):796-808. PubMed ID: 38455414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation.
    Wang X; Bai Y; Wang B
    J Inflamm Res; 2024; 17():1805-1820. PubMed ID: 38523681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.
    Miyashita H; Bevins NJ; Thangathurai K; Lee S; Pabla S; Nesline MK; Glenn ST; Conroy JM; DePietro P; Rubin E; Sicklick JK; Kato S; Kurzrock R
    Am J Cancer Res; 2024; 14(5):2240-2252. PubMed ID: 38859855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Immunotherapy guided by molecular profiling of tumors: illustrative cases and literature review.
    Ozdogan M; Papadopoulou E; Metaxa-Mariatou V; Kapetsis G; Meintani A; Florou-Chatzigiannidou C; Yildiz A; Cakir MO; Kirca O; Nasioulas G
    Front Med (Lausanne); 2024; 11():1403056. PubMed ID: 39045411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
    Muquith M; Espinoza M; Elliott A; Xiu J; Seeber A; El-Deiry W; Antonarakis ES; Graff SL; Hall MJ; Borghaei H; Hoon DSB; Liu SV; Ma PC; McKay RR; Wise-Draper T; Marshall J; Sledge GW; Spetzler D; Zhu H; Hsiehchen D
    Nat Cancer; 2024 Mar; ():. PubMed ID: 38528112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
    Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
    Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.